Interaction of obesity and infections

Obesity Reviews

Volumn 16, Issue 12, 2015, Pages 1017-1029

  Dhurandhar, N V ^a   Bailey, D ^a   Thomas, D ^b  

^a TEXAS TECH UNIVERSITY   (United States)

^b MONTCLAIR STATE UNIVERSITY   (United States)

Author keywords

Infection; Obesity

Indexed keywords

ANTIBIOTIC AGENT; ANTIVIRUS AGENT; VACCINE; ANTIINFECTIVE AGENT; BACTERIUM ANTIBODY; VIRUS ANTIBODY;

ANTIBIOTIC THERAPY; ANTIVIRAL THERAPY; BODY MASS; BODY WEIGHT; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; ERADICATION THERAPY; FAT MASS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HEPATITIS B; HUMAN; HUMAN ADENOVIRUS 36; HUMAN ADENOVIRUS C; HUMAN ADENOVIRUS INFECTION; INFECTION; INFECTION PREVENTION; INFECTION SENSITIVITY; INFLUENZA A (H1N1); INTRAABDOMINAL FAT; NONHUMAN; OBESITY; PARASITOSIS; PERIODONTAL DISEASE; POSTOPERATIVE INFECTION; REVIEW; STOMACH ULCER; VACCINATION; WAIST CIRCUMFERENCE; WAIST HIP RATIO; WEIGHT GAIN; ADENOVIRIDAE; COMPLICATION; DISEASE PREDISPOSITION; IMMUNOLOGY; INFLUENZA; INFLUENZA A VIRUS (H1N1); ISOLATION AND PURIFICATION; MICROBIOLOGY; SEVERITY OF ILLNESS INDEX; SURGICAL INFECTION; VIROLOGY;

ADENOVIRIDAE; ADENOVIRUS INFECTIONS, HUMAN; ANTI-BACTERIAL AGENTS; ANTIBODIES, BACTERIAL; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; BODY MASS INDEX; DISEASE SUSCEPTIBILITY; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; OBESITY; SEVERITY OF ILLNESS INDEX; SURGICAL WOUND INFECTION; WEIGHT GAIN;

EID: 84947869330     PISSN: 14677881     EISSN: 1467789X     Source Type: Journal    
DOI: 10.1111/obr.12320     Document Type: Review

References (217)

1. Ng M, Fleming T, Robinson M etal. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014; 384: 776-781.
2. Fernandez-Real JM, Ferri MJ, Vendrell J, Ricart W. Burden of infection and fat mass in healthy middle-aged men. Obesity (Silver Spring) 2007; 15: 245-252.
3. Cocoros NM, Lash TL, Norgaard M, Farkas DK, DeMaria A Jr, Sorensen HT. Hospitalized prenatal and childhood infections and obesity in Danish male conscripts. Ann Epidemiol 2013; 23: 307-313.
4. Dhurandhar NV. A framework for identification of infections that contribute to human obesity. Lancet Infect Dis 2011; 11: 963-969.
5. Liberati A, Altman DG, Tetzlaff J etal. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009; 151: W65-W94.
6. Jang EJ, Park SW, Park JS etal. The influence of the eradication of Helicobacter pylori on gastric ghrelin, appetite, and body mass index in patients with peptic ulcer disease. J Gastroenterol Hepatol 2008; 23(Suppl. 2): S278-S285.
7. Jalalzadeh M, Ghadiani MH, Mousavinasab N. Association between Helicobacter pylori infection and body mass index, before and after eradication of infection in hemodialysis patients. J Nephropathol 2012; 1: 170-176.
8. Fujiwara Y, Higuchi K, Arafa UA etal. Long-term effect of Helicobacter pylori eradication on quality of life, body mass index, and newly developed diseases in Japanese patients with peptic ulcer disease. Hepatogastroenterology 2002; 49: 1298-1302.
9. Azuma T, Suto H, Ito Y etal. Eradication of Helicobacter pylori infection induces an increase in body mass index. Aliment Pharmacol Ther 2002; 16(Suppl. 2): 240-244.
10. Kamada T, Hata J, Kusunoki H etal. Eradication of Helicobacter pylori increases the incidence of hyperlipidaemia and obesity in peptic ulcer patients. Dig Liver Dis 2005; 37: 39-43.
11. Lane JA, Murray LJ, Harvey IM, Donovan JL, Nair P, Harvey RF. Randomised clinical trial: Helicobacter pylori eradication is associated with a significantly increased body mass index in a placebo-controlled study. Aliment Pharmacol Ther 2011; 33: 922-929.
12. Suto H, Yamazaki Y, Yoshida I etal. The effects of Helicobacter pylori eradication on body mass index and dyspeptic symptoms. Digestion 2009; 79: 235-242.
13. Wu MS, Lee WJ, Wang HH, Huang SP, Lin JT. A case-control study of association of Helicobacter pylori infection with morbid obesity in Taiwan. Arch Intern Med 2005; 165: 1552-1555.
14. Francois F, Roper J, Joseph N etal. The effect of H. pylori eradication on meal-associated changes in plasma ghrelin and leptin. BMC Gastroenterol 2011; 11: 37.
15. Pacifico L, Anania C, Osborn JF etal. Long-term effects of Helicobacter pylori eradication on circulating ghrelin and leptin concentrations and body composition in prepubertal children. Eur J Endocrinol 2008; 158: 323-332.
16. Osawa H, Kita H, Ohnishi H etal. Changes in plasma ghrelin levels, gastric ghrelin production, and body weight after Helicobacter pylori cure. J Gastroenterol 2006; 41: 954-961.
17. Pellicano R, Oliaro E, Fagoonee S etal. Clinical and biochemical parameters related to cardiovascular disease after Helicobacter pylori eradication. Int Angiol 2009; 28: 469-473.
18. Ioannou GN, Weiss NS, Kearney DJ. Is Helicobacter pylori seropositivity related to body mass index in the United States? Aliment Pharmacol Ther 2005; 21: 765-772.
19. Kyriazanos ID, Sfiniadakis I, Gizaris V etal. The incidence of Helicobacter pylori infection is not increased among obese young individuals in Greece. J Clin Gastroenterol 2002; 34: 541-546.
20. Shiotani A, Miyanishi T, Uedo N, Iishi H. Helicobacter pylori infection is associated with reduced circulating ghrelin levels independent of body mass index. Helicobacter 2005; 10: 373-378.
21. Torisu T, Matsumoto T, Takata Y etal. Atrophic gastritis, but not antibody to Helicobacter pylori, is associated with body mass index in a Japanese population. J Gastroenterol 2008; 43: 762-766.
22. Gerig R, Ernst B, Wilms B, Thurnheer M, Schultes B. Gastric Helicobacter pylori infection is associated with adverse metabolic traits in severely obese subjects. Obesity (Silver Spring) 2013; 21: 535-537.
23. Shin DW, Kwon HT, Kang JM etal. Association between metabolic syndrome and Helicobacter pylori infection diagnosed by histologic status and serological status. J Clin Gastroenterol 2012; 46: 840-845.
24. Arslan E, Atilgan H, Yavasoglu I. The prevalence of Helicobacter pylori in obese subjects. Eur J Intern Med 2009; 20: 695-697.
25. Ekesbo R, Nilsson PM, Lindholm LH, Persson K, Wadstrom T. Combined seropositivity for H. pylori and C. pneumoniae is associated with age, obesity and social factors. J Cardiovasc Risk 2000; 7: 191-195.
26. Erim T, Cruz-Correa MR, Szomstein S, Velis E, Rosenthal R. Prevalence of Helicobacter pylori seropositivity among patients undergoing bariatric surgery: a preliminary study. World J Surg 2008; 32: 2021-2025.
27. Longo-Mbenza B, Nkondi Nsenga J, Vangu Ngoma D. Prevention of the metabolic syndrome insulin resistance and the atherosclerotic diseases in Africans infected by Helicobacter pylori infection and treated by antibiotics. Int J Cardiol 2007; 121: 229-238.
28. Perdichizzi G, Bottari M, Pallio S, Fera MT, Carbone M, Barresi G. Gastric infection by Helicobacter pylori and antral gastritis in hyperglycemic obese and in diabetic subjects. New Microbiol 1996; 19: 149-154.
29. Rosenstock SJ, Jorgensen T, Andersen LP, Bonnevie O. Association of Helicobacter pylori infection with lifestyle, chronic disease, body-indices, and age at menarche in Danish adults. Scand J Public Health 2000; 28: 32-40.
30. Russo A, Eboli M, Pizzetti P etal. Determinants of Helicobacter pylori seroprevalence among Italian blood donors. Eur J Gastroenterol Hepatol 1999; 11: 867-873.
31. Thjodleifsson B, Olafsson I, Gislason D, Gislason T, Jogi R, Janson C. Infections and obesity: a multinational epidemiological study. Scand J Infect Dis 2008; 40: 381-386.
32. Thjodleifsson B, Asbjornsdottir H, Sigurjonsdottir RB etal. Seroprevalence of Helicobacter pylori and cagA antibodies in Iceland, Estonia and Sweden. Scand J Infect Dis 2007; 39: 683-689.
33. Zheng Y, Liu M, Shu H, Chen Z, Liu G, Zhang Y. Relationship between oral problems and Helicobacter pylori infection. Arch Oral Biol 2014; 59: 938-943.
34. Robinson CM, Singh G, Lee JY etal. Molecular evolution of human adenoviruses. Sci Rep 2013; 3: 1812. doi:10.1038/srep01812.
35. Dhurandhar NV, Kulkarni PR, Ajinkya SM, Sherikar AA, Atkinson RL. Association of adenovirus infection with human obesity. Obes Res 1997; 5: 464-469.
36. Bil-Lula I, Stapor S, Krzywonos-Zawadzka A, Wozniak M. Is there any link between visceral obesity and adenovirus infections in the polish population? Adv Clin Exp Med 2014; 23: 415-422.
37. Cakmakliogullari EK, Sanlidag T, Ersoy B, Akcali S, Var A, Cicek C. Are human adenovirus-5 and 36 associated with obesity in children? J Investig Med 2014; 62: 821-824.
38. Bil-Lula I, Sochocka M, Zatonska K, Szuba A, Sawicki G, Wozniak M. Adenovirus type 9 enhances differentiation and decreases cytokine release from preadipocytes. J Med Virol 2014; 8: 230-239.
39. Gabbert C, Donohue M, Arnold J, Schwimmer JB. Adenovirus 36 and obesity in children and adolescents. Pediatrics 2010; 126: 721-726.
40. Berger P, Pollock N, Laing E etal. Association of adenovirus 36 infection with adiposity and inflammatory-related markers in children. J Clin Endocrinol Metab 2014; 99: 3240-3246.
41. Voss JD, Burnett DG, Olsen CH, Haverkos HW, Atkinson RL. Adenovirus 36 antibodies associated with clinical diagnosis of overweight/obesity but not BMI Gain: a military cohort study. J Clin Endocrinol Metab 2014; 99: E1708-E1712.
42. Almgren M, Atkinson R, He J etal. Adenovirus-36 is associated with obesity in children and adults in Sweden as determined by rapid ELISA. PLoS ONE 2012; 7: e41652.
43. Atkinson RL, Dhurandhar NV, Allison DB etal. Human adenovirus-36 is associated with increased body weight and paradoxical reduction of serum lipids. Int J Obes (Lond) 2005; 29: 281-286.
44. Atkinson RL, Lee I, Shin HJ, He J. Human adenovirus-36 antibody status is associated with obesity in children. Int J Pediatr Obes 2010; 5: 157-160.
45. Broderick MP, Hansen CJ, Irvine M etal. Adenovirus 36 seropositivity is strongly associated with race and gender, but not obesity, among US military personnel. Int J Obes (Lond) 2010; 34: 302-308.
46. Goossens VJ, deJager SA, Grauls GE etal. Lack of evidence for the role of human adenovirus-36 in obesity in a European cohort. Obesity (Silver Spring) 2011; 19: 220-221.
47. Parra-Rojas I, Del Moral-Hernandez O, Salgado-Bernabe AB, Guzman-Guzman IP, Salgado-Goytia L, Munoz-Valle JF. Adenovirus-36 seropositivity and its relation with obesity and metabolic profile in children. Int J Endocrinol 2013; 2013: 463194.
48. Trovato GM, Castro A, Tonzuso A etal. Human obesity relationship with Ad36 adenovirus and insulin resistance. Int J Obes (Lond) 2009; 33: 1402-1409.
49. Trovato GM, Martines GF, Garozzo A etal. Ad36 adipogenic adenovirus in human non-alcoholic fatty liver disease. Liver Int 2010; 30: 184-190.
50. Trovato GM, Martines GF, Trovato FM etal. Adenovirus-36 seropositivity enhances effects of nutritional intervention on obesity, bright liver, and insulin resistance. Dig Dis Sci 2012; 57: 535-544.
51. Aldhoon-Hainerova I, Zamrazilova H, Atkinson RL etal. Clinical and laboratory characteristics of 1179 Czech adolescents evaluated for antibodies to human adenovirus 36. Int J Obes (Lond) 2014; 38: 285-291.
52. Na HN, Kim J, Lee HS etal. Association of human adenovirus-36 in overweight Korean adults. Int J Obes (Lond) 2012; 36: 281-285.
53. Lin W, Dubuisson O, Rubicz R etal. Long term changes in adiposity and glycemic control are associated with past adenovirus infection. Diabetes Care 2013; 36: 701-707.
54. Vander Wal JS, Huelsing J, Dubuisson O, Dhurandhar NV. An observational study of the association between adenovirus 36 antibody status and weight loss among youth. Obes Facts 2013; 6: 269-278.
55. Amri R, Bordeianou LG, Sylla P, Berger DL. Obesity, outcomes and quality of care: body mass index increases the risk of wound-related complications in colon cancer surgery. Am J Surg 2014; 207: 17-23.
56. Arabshahi KS, Koohpayezade J. Investigation of risk factors for surgical wound infection among teaching hospitals in Tehran. Int Wound J 2006; 3: 59-62.
57. Bennett WM, McEvoy KM, Henell KR, Pidikiti S, Douzdjian V, Batiuk T. Kidney transplantation in the morbidly obese: complicated but still better than dialysis. Clin Transplant 2011; 25: 401-405.
58. Bickenbach KA, Denton B, Gonen M, Brennan MF, Coit DG, Strong VE. Impact of obesity on perioperative complications and long-term survival of patients with gastric cancer. Ann Surg Oncol 2013; 20: 780-787.
59. Birkmeyer NJ, Charlesworth DC, Hernandez F etal. Obesity and risk of adverse outcomes associated with coronary artery bypass surgery. Northern New England Cardiovascular Disease Study Group. Circulation 1998; 97: 1689-1694.
60. Christou NV, Jarand J, Sylvestre JL, McLean AP. Analysis of the incidence and risk factors for wound infections in open bariatric surgery. Obes Surg 2004; 14: 16-22.
61. Chun YS, Schwartz MA, Gu X, Lipsitz SR, Carty MJ. Body mass index as a predictor of postoperative complications in reduction mammaplasty. Plast Reconstr Surg 2012; 129: 228e-233.
62. Cies JJ, Chan S, Hossain J, Brenn BR, Di Pentima MC. Influence of body mass index and antibiotic dose on the risk of surgical site infections in pediatric clean orthopedic surgery. Surg Infect (Larchmt) 2012; 13: 371-376.
63. Conner SN, Verticchio JC, Tuuli MG, Odibo AO, Macones GA, Cahill AG. Maternal obesity and risk of postcesarean wound complications. Am J Perinatol 2014; 31: 299-304.
64. Daneman N, Lu H, Redelmeier DA. Discharge after discharge: predicting surgical site infections after patients leave hospital. J Hosp Infect 2010; 75: 188-194.
65. Davies DA, Yanchar NL. Appendicitis in the obese child. J Pediatr Surg 2007; 42: 857-861.
66. Delgado-Rodriguez M, Medina-Cuadros M, Martinez-Gallego G, Sillero-Arenas M. Usefulness of intrinsic surgical wound infection risk indices as predictors of postoperative pneumonia risk. J Hosp Infect 1997; 35: 269-276.
67. Dossett LA, Dageforde LA, Swenson BR etal. Obesity and site-specific nosocomial infection risk in the intensive care unit. Surg Infect (Larchmt) 2009; 10: 137-142.
68. Friedman ND, Sexton DJ, Connelly SM, Kaye KS. Risk factors for surgical site infection complicating laminectomy. Infect Control Hosp Epidemiol 2007; 28: 1060-1065.
69. Fuji S, Kim SW, Yoshimura K etal. Possible association between obesity and posttransplantation complications including infectious diseases and acute graft-versus-host disease. Biol Blood Marrow Transplant 2009; 15: 73-82.
70. Grady KL, White-Williams C, Naftel D etal. Are preoperative obesity and cachexia risk factors for post heart transplant morbidity and mortality: a multi-institutional study of preoperative weight-height indices. Cardiac Transplant Research Database (CTRD) Group. J Heart Lung Transplant 1999; 18: 750-763.
71. Grant JA, Viens N, Bolognesi MP, Olson SA, Cook CE. Two-year outcomes in primary THA in obese male veterans administration medical center patients. Rheumatol Int 2008; 28: 1105-1109.
72. Greenblatt DY, Kelly KJ, Rajamanickam V etal. Preoperative factors predict perioperative morbidity and mortality after pancreaticoduodenectomy. Ann Surg Oncol 2011; 18: 2126-2135.
73. Hirao M, Tsujinaka T, Imamura H etal. Overweight is a risk factor for surgical site infection following distal gastrectomy for gastric cancer. Gastric Cancer 2013; 16: 239-244.
74. House MG, Fong Y, Arnaoutakis DJ etal. Preoperative predictors for complications after pancreaticoduodenectomy: impact of BMI and body fat distribution. J Gastrointest Surg 2008; 12: 270-278.
75. Itani KM, Jensen EH, Finn TS, Tomassini JE, Abramson MA. Effect of body mass index and ertapenem versus cefotetan prophylaxis on surgical site infection in elective colorectal surgery. Surg Infect (Larchmt) 2008; 9: 131-137.
76. Kaye KS, Marchaim D, Chen TY etal. Predictors of nosocomial bloodstream infections in older adults. J Am Geriatr Soc 2011; 59: 622-627.
77. Khalil GM, Al Shobaili HA, Alzolibani A, Al Robaee A. Relationship between obesity and other risk factors and skin disease among adult Saudi population. J Egypt Public Health Assoc 2011; 86: 56-62.
78. Kim J, Hammar N, Jakobsson K, Luepker RV, McGovern PG, Ivert T. Obesity and the risk of early and late mortality after coronary artery bypass graft surgery. Am Heart J 2003; 146: 555-560.
79. Young H, Knepper B, Vigil C, Miller A, Carey JC, Price CS. Sustained reduction in surgical site infection after abdominal hysterectomy. Surg Infect (Larchmt) 2013; 14: 460-463.
80. Kurmann A, Vorburger SA, Candinas D, Beldi G. Operation time and body mass index are significant risk factors for surgical site infection in laparoscopic sigmoid resection: a multicenter study. Surg Endosc 2011; 25: 3531-3534.
81. Lee ES, Santilli SM, Olson MM, Kuskowski MA, Lee JT. Wound infection after infrainguinal bypass operations: multivariate analysis of putative risk factors. Surg Infect (Larchmt) 2000; 1: 257-263.
82. Linam WM, Margolis PA, Staat MA etal. Risk factors associated with surgical site infection after pediatric posterior spinal fusion procedure. Infect Control Hosp Epidemiol 2009; 30: 109-116.
83. Lu JC, Grayson AD, Jha P, Srinivasan AK, Fabri BM. Risk factors for sternal wound infection and mid-term survival following coronary artery bypass surgery. Eur J Cardiothorac Surg 2003; 23: 943-949.
84. Lynch RJ, Ranney DN, Shijie C, Lee DS, Samala N, Englesbe MJ. Obesity, surgical site infection, and outcome following renal transplantation. Ann Surg 2009; 250: 1014-1020.
85. Macha M, Molina EJ, Franco M etal. Pre-transplant obesity in heart transplantation: are there predictors of worse outcomes? Scand Cardiovasc J 2009; 43: 304-310.
86. Manilich E, Vogel JD, Kiran RP, Church JM, Seyidova-Khoshknabi D, Remzi FH. Key factors associated with postoperative complications in patients undergoing colorectal surgery. Dis Colon Rectum 2013; 56: 64-71.
87. Merkow RP, Bilimoria KY, McCarter MD, Bentrem DJ. Effect of body mass index on short-term outcomes after colectomy for cancer. J Am Coll Surg 2009; 208: 53-61.
88. Nagachinta T, Stephens M, Reitz B, Polk BF. Risk factors for surgical-wound infection following cardiac surgery. J Infect Dis 1987; 156: 967-973.
89. Pieracci F, Hydo L, Eachempati S, Pomp A, Shou J, Barie PS. Higher body mass index predicts need for insulin but not hyperglycemia, nosocomial infection, or death in critically ill surgical patients. Surg Infect (Larchmt) 2008; 9: 121-130.
90. Rahmanian PB, Adams DH, Castillo JG, Chikwe J, Bodian CA, Filsoufi F. Impact of body mass index on early outcome and late survival in patients undergoing coronary artery bypass grafting or valve surgery or both. Am J Cardiol 2007; 100: 1702-1708.
91. Rasmussen KL, Neumann G, Ljungstrom B, Hansen V, Lauszus FF. The influence of body mass index on the prevalence of complications after vaginal and abdominal hysterectomy. Acta Obstet Gynecol Scand 2004; 83: 85-88.
92. Raymond AL, Kfoury AG, Bishop CJ etal. Obesity and left ventricular assist device driveline exit site infection. ASAIO J 2010; 56: 57-60.
93. Ruiz-Tovar J, Oller I, Llavero C etal. Pre-operative and early post-operative factors associated with surgical site infection after laparoscopic sleeve gastrectomy. Surg Infect (Larchmt) 2013; 14: 369-373.
94. Sagi HC, Dziadosz D, Mir H, Virani N, Olson C. Obesity, leukocytosis, embolization, and injury severity increase the risk for deep postoperative wound infection after pelvic and acetabular surgery. J Orthop Trauma 2013; 27: 6-10.
95. Schoenfeld AJ, Carey PA, Cleveland AW 3rd, Bader JO, Bono CM. Patient factors, comorbidities, and surgical characteristics that increase mortality and complication risk after spinal arthrodesis: a prognostic study based on 5, 887 patients. Spine J 2013; 13: 1171-1179.
96. Seligman LC, Duncan BB, Branchtein L, Gaio DS, Mengue SS, Schmidt MI. Obesity and gestational weight gain: cesarean delivery and labor complications. Rev Saude Publica 2006; 40: 457-465.
97. Seim BE, Tonnessen T, Woldbaek PR. Triclosan-coated sutures do not reduce leg wound infections after coronary artery bypass grafting. Interact Cardiovasc Thorac Surg 2012; 15: 411-415.
98. Sems SA, Johnson M, Cole PA, Byrd CT, Templeman DC, Minnesota Orthopaedic Trauma G. Elevated body mass index increases early complications of surgical treatment of pelvic ring injuries. J Orthop Trauma 2010; 24: 309-314.
99. Serrano PE, Khuder SA, Fath JJ. Obesity as a risk factor for nosocomial infections in trauma patients. J Am Coll Surg 2010; 211: 61-67.
100. Smith RL, Bohl JK, McElearney ST etal. Wound infection after elective colorectal resection. Ann Surg 2004; 239: 599-605, discussion 05-7.
101. Turtiainen J, Saimanen E, Partio T etal. Surgical wound infections after vascular surgery: prospective multicenter observational study. Scand J Surg 2010; 99: 167-172.
102. Waisbren E, Rosen H, Bader AM, Lipsitz SR, Rogers SO Jr, Eriksson E. Percent body fat and prediction of surgical site infection. J Am Coll Surg 2010; 210: 381-389.
103. Wurzinger B, Dunser MW, Wohlmuth C etal. The association between body-mass index and patient outcome in septic shock: a retrospective cohort study. Wien Klin Wochenschr 2010; 122: 31-36.
104. Yap CH, Mohajeri M, Yii M. Obesity and early complications after cardiac surgery. Med J Aust 2007; 186: 350-354.
105. Yap CH, Zimmet A, Mohajeri M, Yii M. Effect of obesity on early morbidity and mortality following cardiac surgery. Heart Lung Circ 2007; 16: 31-36.
106. Zahr F, Genovese E, Mathier M etal. Obese patients and mechanical circulatory support: weight loss, adverse events, and outcomes. Ann Thorac Surg 2011; 92: 1420-1426.
107. Corrales-Medina VF, Valayam J, Serpa JA, Rueda AM, Musher DM. The obesity paradox in community-acquired bacterial pneumonia. Int J Infect Dis 2011; 15: e54-e57.
108. Sharma V, Verma PK, Gupta S, Sharma A. Mortality from Influenza A/H1N1 in a tertiary care teaching institution in North India. J Infect Dev Ctries 2010; 4: 468-471.
109. Lopez-Delgado JC, Rovira A, Esteve F etal. Thrombocytopenia as a mortality risk factor in acute respiratory failure in H1N1 influenza. Swiss Med Wkly 2013; 143: w13788.
110. Beleigoli AM, Ribeiro AL, Diniz Mde F, Lima-Costa MF, Boersma E. The 'obesity paradox' in an elderly population with a high prevalence of Chagas disease: the 10-year follow-up of the Bambui (Brazil) Cohort Study of Aging. Int J Cardiol 2013; 166: 523-526.
111. Jung US, Choi JS, Ko JH, Lee JH, Park SY, Park SH. Decreased prevalence of high-risk human papillomavirus infection is associated with obesity. Eur J Gynaecol Oncol 2013; 34: 70-74.
112. Abdullahi M, Annibale B, Capoccia D etal. The eradication of Helicobacter pylori is affected by body mass index (BMI). Obes Surg 2008; 18: 1450-1454.
113. Ahmed R, Cooper R, Foisy M, Der E, Kunimoto D. Factors associated with reduced antituberculous serum drug concentrations in patients with HIV-TB coinfection. J Int Assoc Physicians AIDS Care (Chic) 2012; 11: 273-276.
114. Alsio A, Rembeck K, Askarieh G etal. Impact of obesity on the bioavailability of peginterferon-alpha2a and ribavirin and treatment outcome for chronic hepatitis C genotype 2 or 3. PLoS ONE 2012; 7: e37521.
115. Banga N, Guss P, Banga A, Rosenman KD. Incidence and variables associated with inadequate antibody titers after pre-exposure rabies vaccination among veterinary medical students. Vaccine 2014; 32: 979-983.
116. Barbour A, Schmidt S, Rout WR, Ben-David K, Burkhardt O, Derendorf H. Soft tissue penetration of cefuroxime determined by clinical microdialysis in morbidly obese patients undergoing abdominal surgery. Int J Antimicrob Agents 2009; 34: 231-235.
117. Bauer LA, Edwards WA, Dellinger EP, Simonowitz DA. Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients. Eur J Clin Pharmacol 1983; 24: 643-647.
118. Bookstaver PB, Bland CM, Qureshi ZP etal. Safety and effectiveness of daptomycin across a hospitalized obese population: results of a multicenter investigation in the southeastern United States. Pharmacotherapy 2013; 33: 1322-1330.
119. Bressler B, Wang K, Grippo JF, Heathcote EJ. Pharmacokinetics and response of obese patients with chronic hepatitis C treated with different doses of PEG-IFN alpha-2a (40KD) (PEGASYS). Br J Clin Pharmacol 2009; 67: 280-287.
120. Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003; 38: 639-644.
121. Callahan ST, Wolff M, Hill HR, Edwards KM. Impact of body mass index on immunogenicity of pandemic H1N1 vaccine in children and adults. J Infect Dis 2014; 210: 1270-1271.
122. Cerqueira RM, Correia MR, Fernandes CD, Vilar H, Manso MC. Cumulative Helicobacter pylori eradication therapy in obese patients undergoing gastric bypass surgery. Obes Surg 2013; 23: 145-149.
123. Cheatham SC, Fleming MR, Healy DP etal. Steady-state pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese patients. Int J Antimicrob Agents 2013; 41: 52-56.
124. Chung WG, Kim HJ, Choe YG etal. Clinical impacts of hazardous alcohol use and obesity on the outcome of entecavir therapy in treatment-naive patients with chronic hepatitis B infection. Clin Mol Hepatol 2012; 18: 195-202.
125. Crum-Cianflone NF, Roediger M, Eberly LE etal. Obesity among HIV-infected persons: impact of weight on CD4 cell count. AIDS 2010; 24: 1069-1072.
126. de Werra C, Di Micco R, Pilone V etal. Serum in vivo and in vitro activity of single dose of ertapenem in surgical obese patients for prevention of SSIs. Obes Surg 2013; 23: 911-919.
127. Delgado-Borrego A, Healey D, Negre B etal. Influence of body mass index on outcome of pediatric chronic hepatitis C virus infection. J Pediatr Gastroenterol Nutr 2010; 51: 191-197.
128. Economou M, Milionis H, Filis S etal. Baseline cholesterol is associated with the response to antiviral therapy in chronic hepatitis C. J Gastroenterol Hepatol 2008; 23: 586-591.
129. Edmiston CE, Krepel C, Kelly H etal. Perioperative antibiotic prophylaxis in the gastric bypass patient: do we achieve therapeutic levels? Surgery 2004; 136: 738-747.
130. Egawa Y, Ohfuji S, Fukushima W etal. Immunogenicity of influenza A(H1N1)pdm09 vaccine in patients with diabetes mellitus: with special reference to age, body mass index, and HbA1c. Hum Vaccin Immunother 2014; 10: 1187-1194.
131. Eguchi Y, Mizuta T, Yasutake T etal. High serum leptin is an independent risk factor for non-response patients with low viremia to antiviral treatment in chronic hepatitis C. World J Gastroenterol 2006; 12: 556-560.
132. Eliakim A, Schwindt C, Zaldivar F, Casali P, Cooper DM. Reduced tetanus antibody titers in overweight children. Autoimmunity 2006; 39: 137-141.
133. Freeman JT, Anderson DJ, Hartwig MG, Sexton DJ. Surgical site infections following bariatric surgery in community hospitals: a weighty concern? Obes Surg 2011; 21: 836-840.
134. Hall RG 2nd, Payne KD, Bain AM etal. Multicenter evaluation of vancomycin dosing: emphasis on obesity. Am J Med 2008; 121: 515-518.
135. Haugaard SB, Andersen O, Hansen BR etal. Insulin-like growth factors, insulin-like growth factor-binding proteins, insulin-like growth factor-binding protein-3 protease, and growth hormone-binding protein in lipodystrophic human immunodeficiency virus-infected patients. Metabolism 2004; 53: 1565-1573.
136. Hites M, Taccone FS, Wolff F etal. Case-control study of drug monitoring of beta-lactams in obese critically ill patients. Antimicrob Agents Chemother 2013; 57: 708-715.
137. Ho VP, Nicolau DP, Dakin GF etal. Cefazolin dosing for surgical prophylaxis in morbidly obese patients. Surg Infect (Larchmt) 2012; 13: 33-37.
138. Hwang SM, Choe KW, Cho SH etal. The adverse events of influenza A (H1N1) vaccination and its risk factors in healthcare personnel in 18 military healthcare units in Korea. Jpn J Infect Dis 2011; 64: 183-189.
139. Ingardia CJ, Kelley L, Steinfeld JD, Wax JR. Hepatitis B vaccination in pregnancy: factors influencing efficacy. Obstet Gynecol 1999; 93: 983-986.
140. Jacobson IM, Brown RS Jr, McCone J etal. Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1. Hepatology 2007; 46: 982-990.
141. Jittamala P, Pukrittayakamee S, Tarning J etal. Pharmacokinetics of orally administered oseltamivir in healthy obese and nonobese Thai subjects. Antimicrob Agents Chemother 2014; 58: 1615-1621.
142. Kays MB, Fleming MR, Cheatham SC, Chung EK, Juenke JM. Comparative pharmacokinetics and pharmacodynamics of doripenem and meropenem in obese patients. Ann Pharmacother 2014; 48: 178-186.
143. Koethe JR, Dee K, Bian A etal. Circulating interleukin-6, soluble CD14, and other inflammation biomarker levels differ between obese and nonobese HIV-infected adults on antiretroviral therapy. AIDS Res Hum Retroviruses 2013; 29: 1019-1025.
144. Lake JE, Tseng CH, Currier JS. A pilot study of telmisartan for visceral adiposity in HIV infection: the metabolic abnormalities, telmisartan, and HIV infection (MATH) trial. PLoS ONE 2013; 8: e58135.
145. Le Bris-Tomczak A, Bedos JP, Billon C, Samdjee F, Le Monnier A. Antibiotic strategy in severe community-acquired pneumococcal pneumonia. Med Mal Infect 2012; 42: 226-234.
146. Lim J, Song YJ, Park WS etal. The immunogenicity of a single dose of hepatitis A virus vaccines (Havrix[R] and Epaxal[R]) in Korean young adults. Yonsei Med J 2014; 55: 126-131.
147. Longo C, Bartlett G, Macgibbon B etal. The effect of obesity on antibiotic treatment failure: a historical cohort study. Pharmacoepidemiol Drug Saf 2013; 22: 970-976.
148. Mangia A, Minerva N, Bacca D etal. Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection. Hepatology 2009; 49: 358-363.
149. Mann HJ, Buchwald H. Cefamandole distribution in serum, adipose tissue, and wound drainage in morbidly obese patients. Drug Intell Clin Pharm 1986; 20: 869-873.
150. Manosuthi W, Sungkanuparph S, Tantanathip P etal. Body weight cutoff for daily dosage of efavirenz and 60-week efficacy of efavirenz-based regimen in human immunodeficiency virus and tuberculosis coinfected patients receiving rifampin. Antimicrob Agents Chemother 2009; 53: 4545-4548.
151. Nishikawa H, Arimoto A, Wakasa T, Kita R, Kimura T, Osaki Y. The relation between obesity and survival after surgical resection of hepatitis C virus-related hepatocellular carcinoma. Gastroenterol Res Pract 2013; 2013: 430438.
152. Ostbye T, Taylor DH Jr, Yancy WS Jr, Krause KM. Associations between obesity and receipt of screening mammography, Papanicolaou tests, and influenza vaccination: results from the Health and Retirement Study (HRS) and the Asset and Health Dynamics Among the Oldest Old (AHEAD) Study. Am J Public Health 2005; 95: 1623-1630.
153. Ovsyannikova IG, White SJ, Larrabee BR, Grill DE, Jacobson RM, Poland GA. Leptin and leptin-related gene polymorphisms, obesity, and influenza A/H1N1 vaccine-induced immune responses in older individuals. Vaccine 2014; 32: 881-887.
154. Pai MP, Lodise TP Jr. Oseltamivir and oseltamivir carboxylate pharmacokinetics in obese adults: dose modification for weight is not necessary. Antimicrob Agents Chemother 2011; 55: 5640-5645.
155. Pevzner L, Swank M, Krepel C, Wing DA, Chan K, Edmiston CE Jr. Effects of maternal obesity on tissue concentrations of prophylactic cefazolin during cesarean delivery. Obstet Gynecol 2011; 117: 877-882.
156. Pondo T, Rose CE Jr, Martin SW etal. Evaluation of sex, race, body mass index and pre-vaccination serum progesterone levels and post-vaccination serum anti-anthrax protective immunoglobulin G on injection site adverse events following anthrax vaccine adsorbed (AVA) in the CDC AVA human clinical trial. Vaccine 2014; 32: 3548-3554.
157. Puzniak LA, Morrow LE, Huang DB, Barreto JN. Impact of weight on treatment efficacy and safety in complicated skin and skin structure infections and nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Ther 2013; 35: 1557-1570.
158. Rich BS, Keel R, Ho VP etal. Cefepime dosing in the morbidly obese patient population. Obes Surg 2012; 22: 465-471.
159. Roberts JA, Lipman J. Optimal doripenem dosing simulations in critically ill nosocomial pneumonia patients with obesity, augmented renal clearance, and decreased bacterial susceptibility. Crit Care Med 2013; 41: 489-495.
160. Roe JL, Fuentes JM, Mullins ME. Underdosing of common antibiotics for obese patients in the ED. Am J Emerg Med 2012; 30: 1212-1214.
161. Ryan DM, Lupinacci RJ, Kartsonis NA. Efficacy and safety of caspofungin in obese patients. Med Mycol 2011; 49: 748-754.
162. Sheridan PA, Paich HA, Handy J etal. Obesity is associated with impaired immune response to influenza vaccination in humans. Int J Obes (Lond) 2012; 36: 1072-1077.
163. Sketris I, Lesar T, Zaske DE, Cipolle RJ. Effect of obesity on gentamicin pharmacokinetics. J Clin Pharmacol 1981; 21: 288-293.
164. Stein GE, Schooley SL, Peloquin CA etal. Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis. Ann Pharmacother 2005; 39: 427-432.
165. Sturm AW, Allen N, Rafferty KD etal. Pharmacokinetic analysis of piperacillin administered with tazobactam in critically ill, morbidly obese surgical patients. Pharmacotherapy 2014; 34: 28-35.
166. Talbot HK, Coleman LA, Crimin K etal. Association between obesity and vulnerability and serologic response to influenza vaccination in older adults. Vaccine 2012; 30: 3937-3943.
167. Gibbs H, Broom J, Brown J etal. The impact of obesity on drug prescribing in primary care. Br J Gen Pract 2005; 55: 743-749.
168. Testino G, Sumberaz A, Ancarani AO etal. Influence of body mass index, cholesterol, triglycerides and steatosis on pegylated interferon alfa-2a and ribavirin treatment for recurrent hepatitis C in patients transplanted for HCV and alcoholic cirrhosis. Hepatogastroenterology 2009; 56: 501-503.
169. Thorne-Humphrey LM, Goralski KB, Slayter KL etal. Oseltamivir pharmacokinetics in morbid obesity (OPTIMO trial). J Antimicrob Chemother 2011; 66: 2083-2091.
170. Toma O, Suntrup P, Stefanescu A, London A, Mutch M, Kharasch E. Pharmacokinetics and tissue penetration of cefoxitin in obesity: implications for risk of surgical site infection. Anesth Analg 2011; 113: 730-737.
171. Van Wart S, Phillips L, Ludwig EA etal. Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother 2004; 48: 4766-4777.
172. Wacharasint P, Boyd JH, Russell JA, Walley KR. One size does not fit all in severe infection: obesity alters outcome, susceptibility, treatment, and inflammatory response. Crit Care 2013; 17: R122.
173. Walsh MJ, Jonsson JR, Richardson MM etal. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 2006; 55: 529-535.
174. Weber DJ, Rutala WA, Samsa GP, Santimaw JE, Lemon SM. Obesity as a predictor of poor antibody response to hepatitis B plasma vaccine. JAMA 1985; 254: 3187-3189.
175. Young KM, Gray CM, Bekker LG. Is obesity a risk factor for vaccine non-responsiveness? PLoS ONE 2013; 8: e82779.
176. Zakrison TL, Hille DA, Namias N. Effect of body mass index on treatment of complicated intra-abdominal infections in hospitalized adults: comparison of ertapenem with piperacillin-tazobactam. Surg Infect (Larchmt) 2012; 13: 38-42.
177. Zhang Y, Martin SW, Rose CE Jr etal. Evaluation of body mass index, pre-vaccination serum progesterone levels and anti-anthrax protective antigen immunoglobulin G on injection site adverse events following anthrax vaccination in women. Pharmacoepidemiol Drug Saf 2008; 17: 1060-1067.
178. Zuza EP, Barroso EM, Carrareto AL etal. The role of obesity as a modifying factor in patients undergoing non-surgical periodontal therapy. J Periodontol 2011; 82: 676-682.
179. Diaz E, Martin-Loeches I, Canadell L etal. Corticosteroid therapy in patients with primary viral pneumonia due to pandemic (H1N1) 2009 influenza. J Infect 2012; 64: 311-318.
180. Montravers P, Dupont H, Bedos JP, Bret P. Tigecycline use in critically ill patients: a multicentre prospective observational study in the intensive care setting. Intensive Care Med 2014; 40: 988-997.
181. Al-Zahrani MS, Alghamdi HS. Effect of periodontal treatment on serum C-reactive protein level in obese and normal-weight women affected with chronic periodontitis. Saudi Med J 2012; 33: 309-314.
182. Hung LQ, de Vries PJ, Giao PT etal. Nutritional status following malaria control in a Vietnamese ethnic minority commune. Eur J Clin Nutr 2005; 59: 891-899.
183. Stitely M, Sweet M, Slain D etal. Plasma and tissue cefazolin concentrations in obese patients undergoing cesarean delivery and receiving differing pre-operative doses of drug. Surg Infect (Larchmt) 2013; 14: 455-459.
184. Na HN, Dubuisson O, Hegde V, Nam JH, Dhurandhar NV. Human adenovirus Ad36 and its E4orf1 gene enhance cellular glucose uptake even in the presence of inflammatory cytokines. Biochimie 2014 [In press]. doi:10.1016/j.biochi.2014.11.005.
185. Hainer V, Hainerova IA, Zamrazilova H. Role of infection in the pathogenesis of obesity. Cas Lek Cesk 2012; 151: 563-567.
186. Dhurandhar NV. When commonsense does not make sense. Int J Obes 2012; 36: 1332-1333.
187. Dhurandhar NV. Insulin sparing action of adenovirus 36 and its E4orf1 protein. J Diabetes Complications 2013; 27: 191-199.
188. La Cava A, Matarese G. The weight of leptin in immunity. Nat Rev Immunol 2004; 4: 371-379.
189. Karlsson EA, Beck MA. The burden of obesity on infectious disease. Exp Biol Med (Maywood) 2010; 235: 1412-1424.
190. de Heredia FP, Gomez-Martinez S, Marcos A. Obesity, inflammation and the immune system. Proc Nutr Soc 2012; 71: 332-338.
191. Gyurko R, Siqueira CC, Caldon N, Gao L, Kantarci A, Van Dyke TE. Chronic hyperglycemia predisposes to exaggerated inflammatory response and leukocyte dysfunction in Akita mice. J Immunol 2006; 177: 7250-7256.
192. Middleman AB, Anding R, Tung C. Effect of needle length when immunizing obese adolescents with hepatitis B vaccine. Pediatrics 2010; 125: e508-e512.
193. Tucker CE, Lockwood AM, Nguyen NH. Antibiotic dosing in obesity: the search for optimum dosing strategies. Clin Obes 2014; 4: 287-295.
194. Janson B, Thursky K. Dosing of antibiotics in obesity. Curr Opin Infect Dis 2012; 25: 634-649.
195. Salehian B, Forman SJ, Kandeel FR, Bruner DE, He J, Atkinson RL. Adenovirus 36 DNA in adipose tissue of patient with unusual visceral obesity. Emerg Infect Dis 2010; 16: 850-852.
196. Blumentals WA, Nevitt A, Peng MM, Toovey S. Body mass index and the incidence of influenza-associated pneumonia in a UK primary care cohort. Influenza Other Respir Viruses 2012; 6: 28-36.
197. Charland KM, Buckeridge DL, Hoen AG etal. Relationship between community prevalence of obesity and associated behavioral factors and community rates of influenza-related hospitalizations in the United States. Influenza Other Respir Viruses 2013; 7: 718-728.
198. Kwong JC, Campitelli MA, Rosella LC. Obesity and respiratory hospitalizations during influenza seasons in Ontario, Canada: a cohort study. Clin Infect Dis 2011; 53: 413-421.
199. Coleman LA, Waring SC, Irving SA, Vandermause M, Shay DK, Belongia EA. Evaluation of obesity as an independent risk factor for medically attended laboratory-confirmed influenza. Influenza Other Respir Viruses 2013; 7: 160-167.
200. Cocoros NM, Lash TL, DeMaria A Jr, Klompas M. Obesity as a risk factor for severe influenza-like illness. Influenza Other Respir Viruses 2014; 8: 25-32.
201. Agostoni C, Zuccotti GV, Gianni ML, D'Auria E, Giovannini M, Riva E. Body mass index development during the first 6 months of life in infants born to human immunodeficiency virus-seropositive mothers. Acta Paediatr 1998; 87: 378-380.
202. Amorosa V, Synnestvedt M, Gross R etal. A tale of 2 epidemics: the intersection between obesity and HIV infection in Philadelphia. J Acquir Immune Defic Syndr 2005; 39: 557-561.
203. Brown TT, Ruppe MD, Kassner R etal. Reduced bone mineral density in human immunodeficiency virus-infected patients and its association with increased central adiposity and postload hyperglycemia. J Clin Endocrinol Metab 2004; 89: 1200-1206.
204. Forrester JE, Tucker KL, Gorbach SL. The effect of drug abuse on body mass index in Hispanics with and without HIV infection. Public Health Nutr 2005; 8: 61-68.
205. Johnsen S, Dolan SE, Fitch KV, Killilea KM, Shifren JL, Grinspoon SK. Absence of polycystic ovary syndrome features in human immunodeficiency virus-infected women despite significant hyperinsulinemia and truncal adiposity. J Clin Endocrinol Metab 2005; 90: 5596-5604.
206. Tate T, Willig AL, Willig JH etal. HIV infection and obesity: where did all the wasting go? Antivir Ther 2012; 17: 1281-1289.
207. Armah KA, McGinnis K, Baker J etal. HIV status, burden of comorbid disease, and biomarkers of inflammation, altered coagulation, and monocyte activation. Clin Infect Dis 2012; 55: 126-136.
208. Genco RJ, Grossi SG, Ho A, Nishimura F, Murayama Y. A proposed model linking inflammation to obesity, diabetes, and periodontal infections. J Periodontol 2005; 76: 2075-2084.
209. Oikarinen R, Syrjala AM, Komulainen K etal. Body mass index and periodontal infection in a sample of non-smoking older individuals. Oral Dis 2014; 20: e25-e30.
210. Prpic J, Kuis D, Glazar I, Ribaric SP. Association of obesity with periodontitis, tooth loss and oral hygiene in non-smoking adults. Cent Eur J Public Health 2013; 21: 196-201.
211. Saxlin T, Suominen-Taipale L, Kattainen A, Marniemi J, Knuuttila M, Ylostalo P. Association between serum lipid levels and periodontal infection. J Clin Periodontol 2008; 35: 1040-1047.
212. Saxlin T, Ylostalo P, Suominen-Taipale L, Aromaa A, Knuuttila M. Overweight and obesity weakly predict the development of periodontal infection. J Clin Periodontol 2010; 37: 1059-1067.
213. Saxlin T, Ylostalo P, Suominen-Taipale L, Mannisto S, Knuuttila M. Association between periodontal infection and obesity: results of the Health 2000 Survey. J Clin Periodontol 2011; 38: 236-242.
214. Ylostalo P, Suominen-Taipale L, Reunanen A, Knuuttila M. Association between body weight and periodontal infection. J Clin Periodontol 2008; 35: 297-304.
215. Campos Ponce M, Incani RN, Pinelli E etal. Are intestinal parasites fuelling the rise in dual burden households in Venezuela? Trans R Soc Trop Med Hyg 2013; 107: 119-123.
216. Reeves GM, Mazaheri S, Snitker S etal. A positive association between T. gondii seropositivity and obesity. Front Public Health 2013; 1: 73.
217. Londono AL, Mejia S, Gomez-Marin JE. Prevalence and risk factors associated with intestinal parasitism in preschool children from the urban area of Calarca, Colombia. Rev Salud Publica (Bogota) 2009; 11: 72-81.